Arrowhead Pharmaceuticals Inc
Kumar expects Alnylam’s market share in HBV to grow from 12.5 percent to 47.5 percent and in AAT from 30 percent to 100 percent. He maintains a Buy rating on the company, while raising the price target from $73 to $89.
Alnylam Will Not Face The Same Risks
Arrowhead’s discontinuation was owing to deaths in "a nonclinical toxicology study in non-human primates using EX[-]1, the company's liver-targeted, intravenously administered delivery vehicle," Kumar wrote. He explained that while EX-1 used the DPC platform, which involved “a second, non-therapeutic agent to promote delivery of the RNAi drug,” Alnylam’s ALN-HBV RNAi assets did not use the DPC technology and, therefore, “should not face similar safety risks.”
Leader In HBV RNAi
In reviewing Arrowhead’s discontinuation and the Phase IIa of Arbutus Biopharma Corp
In a separate note, Kumar
At Last Check
- Alnylam was up 1.72 percent in the pre-market session Wednesday, trading at $46.82.
- Arbutus was up 5.66 percent in Wednesday's pre-market, trading at $2.80.
- Arrowhead was down 60.49 percent at $1.73.
|Oct 2016||Morgan Stanley||Downgrades||Overweight||Equal-weight|
|Oct 2016||Leerink Swann||Downgrades||Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.